click company/industri name report summari
price estim chang
adu re-emerg fomo re-engag maintain hold take pt
deliv strongest volum growth year beat rais safe buy pt
jump stream revenue reacceler hold pt
execut offset headwind maintain buy buy pt
momentum temper softer guid hold pt
track enter clinic uniqu target technolog buy price target
zynteglo manufactur get greenlight europ
bambu launch preview buy price target
chang rare alli valuat especi sector retreat
summari publish mon-fri includ report publish sinc recent edit pleas refer individu report specif public price date
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect invest analyst person independ object view
design invest relev issuer discuss herein
research report uk produc canaccord genuiti limit authoris regul financi conduct author fca report
european issuer non-independ research market commun market abus regul fca conduct busi rule
canaccord genuiti australia limit australian affili global capit market group canaccord genuiti group inc cf tsx recommend
opinion express research report accur reflect analyst person independ object view design invest
import inform pleas see import disclosur begin page document
back index
adu re-emerg fomo re-engag maintain
hold take pt
surpris aducanumab reviv mean becom fear-of-missing-out stori
report yesterday quarter solid adj ep
handili beat estim stronger revenu gross margin lower
expens tax rate much larger stori drove stock
decis surprisingli reviv aducanumab earli alzheim diseas partner
eisai recal stop program base futil analysi
adu emerg engag phase trial downgrad stock
event fear miss fomo key leg buy thesi time
crippl remain construct valuat sinc difficult us
recommend stock mainli cheap still lot uncertainti
investor skeptic unclear whether fda could approv adu base one
success emerg trial support engag fail perhap show trend
appear howev fda bless plan submit biolog
licens applic bla earli news view mean fomo
compon firmli back occupi investor mind share multi-billion ad market
simpli larg ignor acknowledg data present hope ad
commun opportun investor would like wait present
fuller data set clinic trial alzheim diseas ctad confer san
diego ca may abl recommend activ posit
intrigu interest sever question remain data
use note delv detail alreadi present slideshow
short said emerg work especi suffici number
patient expos high-dos aducanumab mean futil analysi came
prematur wrong conclus clearli nuanc number patient
continu exposur high-dos adu factor play said
yet hear convinc explan engag fail although start
month apart vs emerg would also like see carrier statu might
mean whether might somehow influenc label/usag adu approv
limit data set separ recal biib/eisai also earli ad phase
shown earli promis phase prove confus addit data
releas adu potenti fileabl phase
amyloid beta hypothesi back un dead
rais pt ad adu probabl approv
key updat ad aducanumab back model
probabl approv assum us launch eu/japan launch
net start annual price us discount ex-u
base sale earli ad patient us/europe/japan
peak unadjust sale us/eu/japan model
account profit-shar eisai probabl approv adu
vs base case dcf values/shar would
vs base case time includ zero valu
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
diagnost tool
deliv strongest volum growth year beat
rais safe buy pt
deliv strongest volum growth rate y/i sinc
take share labcorp lh hold result gain
live larg health plan expect share gain continu
like meanwhil encourag compani beat though
magnitud rais high enough move stock higher today
think matter guid conserv help repair credibl last year
miss matter setup look good view
rel safe reiter buy rate rais pt
dividend yield believ fit nice mid/larg cap incom portfolio
beat adj ep beat rev
y/i beat volum
beat driven organ volum
expand network access share gain expect
increas throughout beyond ad point volum growth
step certain deal anniversari revenue /req better our/
street includ pama hit unit price
saw benefit y/i patient concess payor test mix
rais guid rais ep guid look conserv us beat
street estim top-lin bottom-lin rais
revenue guid y/i increas
midpoint rais adj ep guid y/i greater
howev high end guid match consensu
model rais rev y/i y/i
rais revenu estim y/i
reiter revenu estim rais adj ep
penni maintain adj ep
estim assum chang expect pama cut
growth new acquisit like conserv
share gain expect continu quest gain health plan access
live anthem horizon georgia indic expect market share
gain continu quest reiter view expand
health plan coverag mark increment billion revenu opportun quest also
continu grow tune points/year howev compani
indic potenti deal get bigger complex take longer
close quest continu target cost save invigor
new lab act revers pama pain investor prudenc warrant
assum chang statu quo pama pain cautious optimist
potenti new lab act bill introduc hous year could
possibl delay next round data report one year expand
scope applic lab includ hospit lab would result better
reimburs lh bill mark progress made acla view
odd pama fix low view lab act free call option pama fix
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
jump stream revenue reacceler hold
maintain hold rate pt intrigu improv gross margin
profil driven three product transit current underway
howev believ time put new money work see improv
organ revenu growth especi workforc solut ws feel
necessari order share break-out
posit posit surpris manag detail long-term
expect gross margin gpm
neg ws growth exclud lared providigm improv basi
point versu ideal believ path double-digit
growth need us get construct share
revenu mix oper incom beat revenu miss cg
in-lin con ws revenu miss cg/con
provid solut revenu slight beat vs cg/con
oper incom beat cg/con
organ workforc solut ws growth need acceler share work
although encourag improv margin profil reacceler
core ws revenu desir divis grew exclud lared
providigm improv slightli growth growth
growth manag allud new product upgrad
nurs compet area video myteam within learn center wrap
around product new resuscit offer could facilit reacceler
also encourag posit uptak resuscit offer
client ad approxim total contract valu
year new offer sign ytd
gross margin discuss encourag although consid saa platform
histor busi mix includ lower-margin content partnership led
mute gpm expans margin profil improv given three transit
underway transit new resuscit offer transit
veriti credenti new saa platform transit new hstream
platform-as-as-servic util azur aw manag guid sustain
gpm middl seem conserv given gpm
step usual conserv charact detail long-term gpm
target begin gpm trend coupl acceler
core ws growth could inertia need get share move higher
oper incom trend guidanc bright spot last quarter
rais oper incom guidanc five time maintain guidanc three
time histor taken conserv stanc guidanc opex
better expect year-do-d howev primarili relat
hire fewer peopl origin expect believ upsid potenti
oper incom base current trend
price target valuat maintain pt base
adj-ebitda estimate discount peer trade
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
aerospac defens
pt
report adjust ep ahead estim
consensu compani total sale repres y/i
increas constant fx commerci aerospac sale grow
space defens sale boost respect constant currenc industri sale
increas constant fx basi wind turbin sale industri key driver
see growth rate step y/i compani report gross oper
margin respect rise bp respect
level seen maintain buy rate adjust price
target
manag lower revenu guidanc reflect impact
ground product manag describ program key
tailwind commerci aero third quarter addit
benefit move howev compani see
step-down product rate approxim
volum result larg step well
fx impact cut top-line guidanc new midpoint
deliveri push right addit color boe
wednesday like shed addit light revenu outlook
look like end compani indic increment headwind
key factor top-lin guidanc reduct
favor commerci aero sale climb demand
margin perform surpass estim compani gross
margin remain impress hover near level repres
bp improv y/i beat estim bp similarli oper
margin prove robust best estim composit
materi took haircut end bp target due impact
engin product prove net tailwind segment oper margin
blow bp expect company-wid increment margin
y/i basi believ strong margin perform
compani continu benefit improv key contributor
strength stock even lower revenu outlook
wind sale begun level current level like ceil go
forward wind turbin busi begin anniversari challeng comp
breakneck growth pace seen manag indic slow growth
rate y/i like signal product line run-rat go forward follow
y/i sale gain first nine month year addit wind farm tax
credit track ceas end
maintain buy rate adjust price target
adjust adj ep estim respect
reflect push-out shipset product continu see top-
line growth in-lin guidanc investor clearli skeptic
potenti upsid consid grow risk around
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
momentum temper softer guid hold pt
snap deliv strong perform across kpi includ user revenu
increment profit android app redesign along platform local
content partnership intern market drive dau growth
new advertis product attract market platform guid
margin soft vs consensu reflect calendar cadenc year one fewer
week holiday difficult compar direct respons alway
advertis encourag snap oper develop think
valuat alreadi reflect lot improv includ continu strong top
line growth busi deliv ebitda margin next year
engag momentum lead anoth dau beat snap ad net dau
roughli doubl estim consensu estim bring total
dau y/i rebuilt android app enabl compani improv
user experi intern market lead increas engag ar
continu differenti dau interact ar almost per day
averag lens creat use len studio date
daili time spent watch discov increas y/i
differ discov channel reach monthli audienc user
repres signific portion snap potenti dau growth compani
ad local languag support sever new market along new content
channel across eight market manag note invest content ar
platform remain top prioriti short-term year game map
two area look scale medium term year
new tool emphasi video lead strong revenu growth continu
improv user engag led third consecut quarter acceler
top-lin growth revenu increas y/i bp q/q arpu
grew y/i q/q compani laid four key area focu
demonstr uniqu natur younger demograph age
age introduc new innov advertis product
deliv measur roi help achiev campaign goal improv sale
market effort expand partnership snap continu introduc
new autom ad tool includ recent launch dynam allow
brand gener person creativ base product catalog real-tim
compani also extend max length video ad three minut includ
unskipp ad transit skippabl six second ad
capabl bid auction goal longer form video view
guidanc lighter expect point profit revenu
guidanc came consensu estim
repres top-lin growth adj ebitda guidanc break-even also
came consensu expect potenti repres first
quarter adj ebitda profit snap
valuat maintain price target base
revenu estim pt also support dcf valuat
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
track enter clinic uniqu
takeaway market manag new york boston
track begin phase earli atreca look ink
strateg partnership
phase start earli biopsi import
atreca phase trial solid tumor start earli includ
multipl tumor biopsi time patient meaning posit open-label
dose escal adapt studi enrol patient advanc tumor
show reactiv preclin studi given safeti concern
identifi preclin work fda allow begin phase reason
dose level view
atreca dose mg/kg cynomolgu monkey meaning
advers effect suggest favor safeti specif human given
target ribonucleoprotein complex believ high specif
decreas chanc side effect await human safeti data phase
strateg drug discoveri partnership showcas target discoveri
believ atreca could announc strateg drug discoveri partnership
interest given compani use bodi immun system find target
atreca use proprietari sequenc identifi antibodi produc immun
system kill cancer -- way let bodi identifi target addit
atreca abil incorpor domain commonli use bi-specif
antibodi drug conjug payload modifi domain augment
maintain buy rate price target atreca base favor view
target discoveri platform phase program expect phase studi
start earli strateg partnership well view compani
technolog uniqu sinc atreca identifi actual antibodi produc immun
system effect cancer respons use antibodi lead test
patient bodi immun system identifi target interest
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
zynteglo manufactur get greenlight europ
take-away ema manufactur issu zynteglo resolv clear
way eu launch
schedul eu launch ema approv zynteglo manufactur
ema approv refin commerci drug product manufactur specif
zynteglo anticip resolut still lift overhang
uncertainti zynteglo could launch earlier year june manufactur
concern eu regard commerci drug product specif
commerci drug manufactur process led delay launch zynteglo
receiv news ema approv today expect zynteglo track initi
patient treatment previous guid compani use apceth
biopharma site manufactur zynteglo eu
anticip moder eu sale ramp zynteglo thalassemia
initi zynteglo launch trajectori beta thalassemia eu could affect
gradual reimburs safeti concern await uptak determin steep
ramp zynteglo could provid transfus independ patient
meaning patient physician data show
thrombot event veno occlus liver diseas vod northstar studi
veno occlus liver diseas addit physician may
long-term safeti cost concern although believ blue payment system
allevi cost issu furthermor prospect pipelin beta
thalassemia could give physician option
maintain buy rate price target base continu belief
best-in-class asset target bcma multipl myeloma
expect addit clinic data expect usag zynteglo europ
somewhat wari given gener caution physician surround gene
therapi usag thalassemia addit sickl cell diseas physician seem
open gene therapi use await detail defin success sickl cell
diseas term continu payment
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
bambu launch preview buy price target
earlier today cinedigm announc hotli anticip preview launch chines
entertain channel bambu one mileston wait
check list preview launch kind beta releas servic first
offer linear view via exist contv stream servic
believ cinedigm largest took cursori look earli offer came
away quit impress contv drastic updat sinc last year
provid clean user friendli organ experi ampl content offer
bambu sit insid live tv tab began us seamlessli ad
resembl higher qualiti spot viewer might expect tradit tv rather
on-line bambu content suppli cinedigm variou chines
avail american audienc english subtitl ad expect
bambu roll-out measur first linear offer avail control
platform like web mobil wider releas scale platform connect
tv time today news probabl catalyst stock signifi us
thing move right direct like posit news come bambu
launch roll-out help avod revenu growth
secondli compani announc yesterday multi-year agreement chines media
distributor starris come almost two year form strateg allianc
purpos yesterday announc seem us like formal
deal addit alreadi suppli content bambu agreement facilit
releas us film china theatric via broadcast tv digit platform
make cinedigm one american media compani access larg
chines film market note initi cinedigm chines film market
close held institut quota foreign film think initi could lead
new revenu sourc cinedigm
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
report stronger-than-expect revenu vs
estim street ep well
estim street howev bearish commentari lower fy
guidanc key takeaway
fy revenu guidanc lower versu
forecast street estim fy ep guidanc cut
versu estim street
result soft impli ep
releas transcript pre-record confer call contain
commentari follow sub-optimal sell-in decis made lower price
pre-tariff level product meaning impact margin
caution go guidanc reduct seen attribut
tariff yet resolut tariff appear far consum traction
new product unclear expect littl repriev share clariti emerg
return normal margin
look color estimate call wednesday morn
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
chang rare alli valuat especi
sector retreat
point view
chang complex best time complex put cap stock
multipl time like much-need correct far much
enthusiasm enterpris softwar investor sell first ask question later
believ broad softwar sector certainli much closer bottom
done go wed bet see anoth turn revenu multipl
compress today ev/r ntm averag meanwhil
lost ceo cfo hand mid-level manag short order compani
face chang step function larger long-term good side equat
primari competit set remain disorgan clearli slow
economi sell larg digit transform deal long-tail payoff difficult
question becom ceo sap better abl control room
convinc larg organ transform center ceo
year bain sap classic legaci softwar compani
made surpris acquisit analyst opinion frequent orthogon
expens howev sap certainli far deeper enterpris custom
relationship ever make transit smoother thu listen
compani say go-forward plan assess reassess rate
remain buy
turnov top announc departur ceo john donaho
move becom presid ceo nike start januari next
year mcdermott serv ceo/co-ceo sap earlier
month replac presid ceo end year donaho
remain ceo transit period retain seat
board june
pre-announc upsid adjust fx subscript revenu bill
respect exceed midpoint guidanc
adjust impact fx durat
updat guidanc full year lower narrow
subscript revenu bill guidanc account impact fx
durat exclud impact compani carri forward
fx-and-duration-adjust beat experienc otherwis neglig chang
guidanc equat fx durat adjust revenu
bill growth respect full year margin guidanc unchang non-
oper margin expect margin
earn model updat releas full financi result tomorrow
octob point releas model updat page herein
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
year weve good fortun meet mani industri giant
pup experi given us pretti good sens pattern
recognit still long road ahead see uipath mani
characterist seen major success came team
big vision tech deliv immedi measur roi innov fuel
adopt util impress custom roster rang
make big bet firm earliest stage discoveri creat horizont
platform case could view entir new layer softwar one
governor scale often realiz potenti use case custom event
like forward attend last week la vega key element get
user commun engag share idea uipath use forum introduc
materi expand platform believ one forward-think
complet suit process autom technolog market autom era
go creat sever signific firm next year weve seen
uipath far indic might accomplish futur
firm investor need keep eye
takeaway forward
enter age autom digit transform initi drive explos
number app system organ typic enterpris
tech silo ever open system make easier sophist folk
integr dispar app averag lob worker still left navig
multipl set tool complet routin task rpa stand chang paradigm
democrat autom innov could fundament chang way
work actual deliv valu digit transform playbook promis
end-to-end platform innov abound one barrier broad rpa adopt
identifi autom opportun accur mapping/docu
acquisit processgold stepshot uipath make discoveri process
significantli easier like lead faster valuabl scale deploy
insight front introduct embed analyt align rpa oper
busi outcom help buyer measur oper effici financi save
driven invest autom could first step toward explicit
outcomes-bas price mechan well wait see model evolv
uipath number impress start april year uipath report
gone preced month today firm
pass custom year ago
includ fortun fortun new custom acquisit
per day doesnt captur expand dynam perhap
intrigu part stori uipath yet share net dollar expans metric
breakneck pace put differ perhap challeng stress senior leader
preserv cultur common mission time tell fast start lead
endur success say certainti weve impress
uipath team technolog growth one watch
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
